ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 To Be Presented At The American Association Of Cancer Research Meeting
Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused
on oncology, announced that preliminary data from a Phase 1 trial of
an oral formulation of picoplatin in patients with solid tumors will be
presented at the 2008 American Association for Cancer Research meeting to
be held from April 12-16 in San Diego, CA. In addition, preclinical data of
picoplatin overcoming platinum resistant small cell lung cancer cells in
platinum resistant cell lines will also be presented at a separate poster
presentation.
Details are as follows:
-- A Phase 1 randomized crossover picoplatin bioavailability
pharmacokinetics and pharmacodynamics study.
Abstract #209, Session ID: Clinical Research 1;
Yee L, Sharma S, Breitz H, Karlin D, Phillips A, Houston S, Saleh M.
General Poster Session Sunday April 13, 8:00 AM PT.
-- Picoplatin overcomes resistance in small cell lung cancer cell lines
treated with other platinum-based chemotherapeutics.
Abstract #713, Session ID: Experimental Molecular Therapeutics 3;
Parham C, Shocron E, McMahon G, Patel N.
General Poster Session Sunday April 13, 8:00 AM PT.
Picoplatin is the Company's lead product candidate under investigation
in three clinical trials.
About Picoplatin
Picoplatin is a chemotherapeutic agent that has an improved safety
profile compared to existing platinum-based chemotherapeutics. It was
designed to overcome platinum resistance associated with the treatment of
solid tumors. Picoplatin has been evaluated in more than 750 patients and
has anti-tumor activity in multiple indications with less severe kidney or
nerve toxicity than is commonly observed with other platinum chemotherapy
drugs.
Poniard is evaluating intravenous picoplatin in an ongoing pivotal
Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse),
in small cell lung cancer. This registrational trial is being conducted
under a Special Protocol Assessment (SPA) from the U.S. Food and Drug
Administration (FDA) and is evaluating overall survival as the primary
endpoint. The Company also is evaluating intravenous picoplatin in two
ongoing Phase 2 clinical trials for the treatment of hormone refractory
prostate cancer (HRPC) and metastatic Colorectal Cancer (mCRC). Oral
picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.
Picoplatin has not been approved by regulatory authority for use in humans.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. For additional information please
visit http://www.poniard.com.
This release contains forward-looking statements, including statements
regarding the Company's business objectives and strategic goals, drug
development plans, results of clinical trials and the potential safety and
efficacy of its products in development. The Company's actual results may
differ materially from those indicated in these forward-looking statements
based on a number of factors, including risks and uncertainties associated
with the Company's research and development activities; the results of
pre-clinical and clinical testing; the receipt and timing of required
regulatory approvals; the market's acceptance of the Company's proposed
products; the Company's anticipated operating losses, need for future
capital and ability to obtain future funding; competition from third
parties; the Company's ability to preserve and protect intellectual
property rights; the Company's dependence on third-party manufacturers and
suppliers; the Company's lack of sales and marketing experience; the
Company's ability to attract and retain key personnel; changes in
technology, government regulation and general market conditions; and the
risks and uncertainties described in the Company's current and periodic
reports filed with the Securities and Exchange Commission (SEC), including
the Company's Annual Report on Form 10-K for the year ended December 31,
2007. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to update any forward-looking
statement to reflect new information, events or circumstances after the
date of this release or to reflect the occurrence of unanticipated events.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc.
http://www.poniard.com
Pumnal Pharmaceuticals Announces date clinice de fazã oralã Picoplatin De la 1 Pentru a fi prezentate la Asociatia Americana de Cancer Research Meeting - Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 To Be Presented At The American Association Of Cancer Research Meeting - articole medicale engleza - startsanatate